ELMIRON BLADDER DRUG LINKED TO VISION LOSS
Elmiron (pentosan polysulfate) bladder infection drug has been linked to vision loss, blindness and retinal toxicity. Conditions related to the use of this drug include:
- Macular Degeneration – Age Related (AMD) or Non Age Related
- Vision impairment/Vision Issues
- Retinal Injury/Damage
- Dark Spots/Difficulty viewing colors
- Eye Disease
As of February 2021, 177 cases are consolidated in New Jersey federal district court and Pennsylvania state courts.
What is Elmiron?
Elmiron (pentosan polysulfate) was approved by the FDA in 1996 as a widely prescribed treatment for the relief of pain and discomfort associated with interstitial cystitis (IC), a chronic, progressive and debilitating urinary bladder disease afflicting primarily women. Developed by Ivax Pharmaceuticals, Inc. is now part of Teva Pharmaceutical Industries Ltd. (January 2006) Elmiron’s track record shows it has generated over $250 million in annual sales.
What’s the Injury from Elmiron?
The drug has been prescribed for bladder infections for decades, but a 2019 study by the American Academy of Ophthalmology indicates there is a link to toxicity of the back of the eye. Three ophthalmologists conducted a review of patients at Kaiser Permanente in Northern California. Their review found almost one-quarter of patients with long term use (10-15 years) of Elmiron had signs of eye damage called macular degeneration and other related side effects.
What Are the Warnings about Vision Loss?
Johnson & Johnson’s subsidiary Jansen Pharmaceutical Cos. implemented its first-ever warning in the Elmiron® label addressing the risk of pigmentary maculopathy in June 2020.